Biohaven Ltd.

NYSE:BHVNHealthcare · Biotechnology

Mkt Cap$2.19B

Float119.76M

Shares O/S151.06M

Inst Own93.1%

SI14.9%

Dilution

PrePre-market+1.52%$14.70

Close$14.480.00%AH$14.48+1.52%Now$14.70

PM VOL10K$ Vol≈$153KRVOL1.86x

Close$14.48+4.17%AH$14.48+1.52%since

Mkt Cap$2.19B

Float119.76M

O/S151.06M

PM VOL10K sh

$ Vol≈$153K

RVOL1.86×

Inst Own93.1%

SI14.9%

Dilution

NYSE:BHVNPre$14.70+1.52%Close$14.48+4.17%

MCap$2.19B

Float119.76M

O/S151.06M

PM VOL10K sh$ Vol≈$153KRVOL1.86×

SI14.9%

Inst Own93.1%

Dilution

Historical Data

Date	Open	High	Low	Close	Volume
Nov 6, 2026	14.23	14.49	13.76	14.48	2,921,603
Nov 5, 2026	15.11	15.11	13.84	13.90	3,472,088
Nov 4, 2026	15.97	16.15	15.12	15.24	1,675,789
Nov 3, 2026	15.46	16.09	15.25	15.61	2,016,838
Nov 2, 2026	15.98	16.11	15.08	15.16	2,592,270
Oct 30, 2026	15.46	16.33	15.12	15.42	3,164,692
Oct 29, 2026	15.46	16.49	15.46	16.49	2,450,829
Oct 28, 2026	15.11	15.87	14.96	15.52	3,149,251
Oct 27, 2026	14.44	15.30	14.13	15.29	2,430,645
Oct 26, 2026	13.94	14.70	13.70	14.45	2,677,188
Oct 23, 2026	15.21	15.37	13.83	13.88	4,693,558
Oct 22, 2026	16.10	16.54	14.45	14.69	30,510,244
Oct 21, 2026	11.90	12.16	11.63	11.75	1,443,717
Oct 20, 2026	11.35	11.85	11.07	11.81	1,527,914
Oct 19, 2026	11.01	11.52	10.87	11.35	1,690,879
Oct 16, 2026	11.31	11.40	10.70	10.78	2,423,734
Oct 15, 2026	10.95	11.66	10.94	11.43	1,448,269
Oct 14, 2026	11.39	11.50	10.82	10.93	1,777,668
Oct 13, 2026	11.79	11.79	11.16	11.42	2,434,063
Oct 12, 2026	11.91	11.99	11.65	11.81	1,623,253

Analyst Coverage

ConsensusBuy

Price Target (median, last 90d)

$20.00+38.1%

Low $19High $30

Ratings Distribution

BUY

HOLD

SELL

TOTAL25

Insider Trades

Insider	Title	Type	Shares	Value	Date
Gentile Kimberly	SVP, Clinical Operations	Grant/Award	1.0K	--	Sep 15, 2026
CHILDS JOHN W	Director	Grant/Award	68.7K	--	Apr 28, 2026
Heffernan Michael Thomas	Director	Grant/Award	68.7K	--	Apr 28, 2026
Bailey Gregory	Director	Grant/Award	68.7K	--	Apr 28, 2026
HUGIN ROBERT J	Director	Grant/Award	68.7K	--	Apr 28, 2026
GREGORY JULIA P	Director	Grant/Award	68.7K	--	Apr 28, 2026

Shareholders

93.1%

Institutional

(305)

2.9%

Insiderⓘ

(8)

5.7%

5%+ Owners

(1)

Unattributed (incl. retail)ⓘ

Institutional93.1%

Insider2.9%

5%+ Beneficial5.7%

Top Shareholders

Name	Shares	%	Source
BlackRock, Inc.	13.2M	8.7%	13F
MONTANOVA CAPITAL, LLC	10.3M	6.8%	13F
STIFEL FINANCIAL CORP	9.9M	6.6%	13F
JANUS HENDERSON GROUP Ltd. · may incl. warrants· filed Jul 2026	8.6M	5.7%	13G
Jupiter Topco LLC	8.6M	5.7%	13F
Woodline Partners LP	7.7M	5.1%	13F
STATE STREET CORP	6.9M	4.6%	13F
INFINITUM ASSET MANAGEMENT, LLC	6.3M	4.1%	13F
D. E. Shaw & Co., Inc.	4.2M	2.8%	13F
AQR CAPITAL MANAGEMENT LLC	4.2M	2.7%	13F

Sources: 13F, Form 4, 13D/13GO/S: 151.1M · as of 26 Oct 2026 · SEC cover page

Insiders & Institutional Holders

Insiders

Gentile KimberlySVP, Clinical Operations
CHILDS JOHN WDirector
Heffernan Michael ThomasDirector
Bailey GregoryDirector
HUGIN ROBERT JDirector
GREGORY JULIA PDirector
Antonijevic IrinaDirector
Mehta KishanDirector
Coric VladChief Executive Officer
Buten MatthewChief Financial Officer

Top institutional holders

About

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.

The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.

In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus.

The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Key Metrics

Market Cap$2.19B

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership93.06%

based on 151.06M shares outstanding

SectorHealthcare

IndustryBiotechnology

ExchangeNYSE

Country

IPO DateSep 23, 2022

Shares Outstanding151.06M

Authorized Shares

Float119.76M

52-Week Range

$7.48$18.57

$14.48(63rd percentile)

Volume

Average Daily Volume3.81M

2.92M today vs 3.81M avg(-23%)

30d Avg

3.81M

60d Avg

3.18M

90d Avg

3.27M

Earnings

Dividend History

No dividend history available

Compliance Status